VPS34 inhibitor 1 (Compound 19), a PIK-III analogue, is primarily utilized in research settings to study the role of VPS34 in cellular processes. It is particularly valuable in investigating autophagy, a critical mechanism for cellular degradation and recycling. By inhibiting VPS34, this compound helps researchers understand how autophagy influences various physiological and pathological conditions, including cancer, neurodegenerative diseases, and immune responses. Additionally, it serves as a tool to explore the interplay between VPS34 and other signaling pathways, aiding in the development of targeted therapies for diseases where autophagy dysregulation plays a key role. Its application extends to drug discovery, where it is used to screen and validate potential therapeutic compounds targeting autophagy-related pathways.